178 related articles for article (PubMed ID: 10223495)
1. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.
Larsson G; Hallén B; Nilvebrant L
Urology; 1999 May; 53(5):990-8. PubMed ID: 10223495
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study.
Rentzhog L; Stanton SL; Cardozo L; Nelson E; Fall M; Abrams P
Br J Urol; 1998 Jan; 81(1):42-8. PubMed ID: 9467475
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.
Van Kerrebroeck PE; Amarenco G; Thüroff JW; Madersbacher HG; Lock MT; Messelink EJ; Soler JM
Neurourol Urodyn; 1998; 17(5):499-512. PubMed ID: 9776013
[TBL] [Abstract][Full Text] [Related]
5. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
Zinner NR; Mattiasson A; Stanton SL
J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
8. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
Ellsworth PI; Borgstein NG; Nijman RJ; Reddy PP
J Urol; 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673
[TBL] [Abstract][Full Text] [Related]
9. The overactive bladder in children: a potential future indication for tolterodine.
Hjälmås K; Hellström AL; Mogren K; Läckgren G; Stenberg A
BJU Int; 2001 Apr; 87(6):569-74. PubMed ID: 11298060
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
Jonas U; Höfner K; Madersbacher H; Holmdahl TH
World J Urol; 1997; 15(2):144-51. PubMed ID: 9144906
[TBL] [Abstract][Full Text] [Related]
11. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
Appell RA; Abrams P; Drutz HP; Van Kerrebroeck PE; Millard R; Wein A
World J Urol; 2001 Apr; 19(2):141-7. PubMed ID: 11374317
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
Jacquetin B; Wyndaele J
Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
[TBL] [Abstract][Full Text] [Related]
13. Tolterodine use for symptoms of overactive bladder.
Ruscin JM; Morgenstern NE
Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
[TBL] [Abstract][Full Text] [Related]
14. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder.
Kreder K; Mayne C; Jonas U
Eur Urol; 2002 Jun; 41(6):588-95. PubMed ID: 12074774
[TBL] [Abstract][Full Text] [Related]
16. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
Swift S; Garely A; Dimpfl T; Payne C;
Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
[TBL] [Abstract][Full Text] [Related]
17. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
Malone-Lee JG; Walsh JB; Maugourd MF
J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
20. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder.
Mattiasson A; Blaakaer J; Høye K; Wein AJ;
BJU Int; 2003 Jan; 91(1):54-60. PubMed ID: 12614251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
